An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020

An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)

Published:2023-05-04 Issue:5 Volume:33 Page:349-369
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Liu Yi-Min¹²,Liou Jing-Ping¹²

Affiliation:

1. School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan

2. TMU Research Center for Drug Discovery, Taipei Medical University, Taipei, Taiwan

Funder

Ministry of Science and Technology, Taiwan

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2023.2219393

Reference75 articles.

1. Differential molecular mechanistic behavior of HDACs in cancer progression

2. The role of epigenetics in T-cell lymphoma

3. Next-generation of selective histone deacetylase inhibitors

4. The emerging roles of HDACs and their therapeutic implications in cancer

5. Shanghai Bioray Biotechnology Co Ltd, East China Normal University. IDO/HDAC double-target compound and synthetic method and application thereof. CN110668992A; 2020

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design of Multi-Target drugs of HDACs and other Anti-Alzheimer related Targets: Current strategies and future prospects in Alzheimer’s diseases therapy;Bioorganic Chemistry;2024-10

2. Potential to use of viral reverse transcriptase inhibitors in oncology;Advances in Molecular Oncology;2024-06-27

3. Chromatin Remodeling-Related PRDM1 Increases Stomach Cancer Proliferation and Is Counteracted by Bromodomain Inhibitor;Journal of Personalized Medicine;2024-02-20

4. Discovery of novel anticancer flavonoids as potential HDAC2 inhibitors: virtual screening approach based on molecular docking, DFT and molecular dynamics simulations studies;3 Biotech;2024-02-18

5. Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency;European Journal of Medicinal Chemistry;2023-12